|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
AU2009204483B2
(en)
|
2008-01-04 |
2014-03-13 |
Intellikine, Llc |
Certain chemical entities, compositions and methods
|
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
WO2010129816A2
(en)
|
2009-05-07 |
2010-11-11 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
NZ600954A
(en)
|
2009-12-22 |
2013-11-29 |
|
Isoindolinone inhibitors of phosphatidylinositol 3-kinase
|
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
KR20180080358A
(ko)
|
2011-01-10 |
2018-07-11 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀린온 및 이의 고체 형태의 제조 방법
|
|
EP2734530A1
(en)
|
2011-07-19 |
2014-05-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013161312A1
(en)
*
|
2012-04-25 |
2013-10-31 |
Raqualia Pharma Inc. |
Pyrrolopyridinone derivatives as ttx-s blockers
|
|
US9611267B2
(en)
|
2012-06-13 |
2017-04-04 |
Incyte Holdings Corporation |
Substituted tricyclic compounds as FGFR inhibitors
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
UA110688C2
(uk)
*
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
IL291945B2
(en)
|
2012-11-01 |
2025-11-01 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
TWI649318B
(zh)
|
2013-04-19 |
2019-02-01 |
英塞特控股公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
RU2018142605A
(ru)
|
2013-09-25 |
2019-02-04 |
Вертекс Фармасьютикалз Инкорпорейтед |
Селективный ингибитор фосфатидилинозитол-3-киназы-гамма
|
|
MX389256B
(es)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
EP4066834A1
(en)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2015160307A1
(en)
*
|
2014-04-16 |
2015-10-22 |
Nanyang Technological University |
Allenamide as an orthogonal handle for selective modification of cysteine in peptides and proteins
|
|
MX373274B
(es)
|
2014-04-23 |
2020-04-16 |
Takeda Pharmaceuticals Co |
Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer.
|
|
CA2952018A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
CA2952025A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
CA2952037A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
US9499523B2
(en)
*
|
2014-06-13 |
2016-11-22 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
|
JP6455995B2
(ja)
|
2014-06-13 |
2019-01-23 |
ギリアード サイエンシーズ， インコーポレイテッド |
ホスファチジルイノシトール３−キナーゼ阻害剤
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
AU2016219822B2
(en)
|
2015-02-20 |
2020-07-09 |
Incyte Holdings Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
WO2017045955A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Basf Se |
Heterobicyclic compounds
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10514986B2
(en)
|
2015-09-30 |
2019-12-24 |
Commvault Systems, Inc. |
Dynamic triggering of block-level backups based on block change thresholds and corresponding file identities in a data storage management system
|
|
ES2989326T3
(es)
|
2015-10-21 |
2024-11-26 |
Otsuka Pharma Co Ltd |
Compuestos de benzolactama como inhibidores de la proteína cinasa
|
|
MX2018004879A
(es)
*
|
2015-10-22 |
2019-02-28 |
Selvita S A |
Nuevos derivados de piridona y su uso como inhibidores de quinasas.
|
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
|
ES2789756T3
(es)
|
2015-12-23 |
2020-10-26 |
Merck Sharp & Dohme |
Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
|
|
WO2017107089A1
(en)
|
2015-12-23 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
WO2017107087A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
CA3015893C
(en)
*
|
2016-03-10 |
2021-11-09 |
Astrazeneca Ab |
Novel inhibitors of phosphatidylinositol 3-kinase gamma
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
JP6814814B2
(ja)
|
2016-03-17 |
2021-01-20 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
|
|
GB201604970D0
(en)
|
2016-03-23 |
2016-05-04 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CA3028718A1
(en)
|
2016-06-24 |
2017-12-28 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
*
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
WO2018112842A1
(en)
|
2016-12-22 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
|
|
WO2018112843A1
(en)
|
2016-12-22 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
GB201706327D0
(en)
|
2017-04-20 |
2017-06-07 |
Otsuka Pharma Co Ltd |
A pharmaceutical compound
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
KR20200010306A
(ko)
|
2017-05-25 |
2020-01-30 |
아락세스 파마 엘엘씨 |
Kras의 공유적 억제제
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
US10945771B2
(en)
|
2017-06-09 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
|
|
JP6647738B2
(ja)
|
2017-06-12 |
2020-02-14 |
矢崎総業株式会社 |
電池パック
|
|
WO2019000238A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Merck Sharp & Dohme Corp. |
5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
|
|
WO2019000237A1
(en)
|
2017-06-27 |
2019-01-03 |
Merck Sharp & Dohme Corp. |
ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
|
|
WO2019000236A1
(en)
|
2017-06-27 |
2019-01-03 |
Merck Sharp & Dohme Corp. |
ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
|
|
KR20210028144A
(ko)
*
|
2018-04-06 |
2021-03-11 |
블랙 벨트 티엑스 리미티드 |
Atf6 저해제 및 그의 용도
|
|
TW201946630A
(zh)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Fgfr抑制劑之鹽
|
|
ES2991427T3
(es)
|
2018-05-04 |
2024-12-03 |
Incyte Corp |
Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
|
|
CA3107168A1
(en)
|
2018-08-01 |
2020-02-06 |
Araxes Pharma Llc |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
|
WO2020102150A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
JP7644023B2
(ja)
*
|
2019-04-10 |
2025-03-11 |
ナンジン ゼンシャイン ファーマシューティカルズ カンパニー リミテッド |
ホスファチジルイノシトール３－キナーゼ阻害剤
|
|
AU2020288610A1
(en)
|
2019-06-04 |
2022-01-27 |
Arcus Biosciences, Inc. |
2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
GEAP202415945A
(en)
|
2019-10-14 |
2024-04-25 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AU2020395185A1
(en)
|
2019-12-04 |
2022-06-02 |
Incyte Corporation |
Derivatives of an FGFR inhibitor
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
KR20250057919A
(ko)
*
|
2020-04-29 |
2025-04-29 |
릴레이 테라퓨틱스, 인크. |
PI3Kα 억제제 및 이의 사용 방법
|
|
EP4249481A4
(en)
*
|
2020-11-20 |
2024-10-30 |
Hefei Institutes of Physical Science, Chinese Academy of Sciences |
DIHYDROISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AND USES THEREOF
|
|
WO2022197577A1
(en)
*
|
2021-03-17 |
2022-09-22 |
Merck Sharp & Dohme Llc |
Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
|
|
EP4323405A1
(en)
|
2021-04-12 |
2024-02-21 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
AR126101A1
(es)
|
2021-06-09 |
2023-09-13 |
Incyte Corp |
Heterociclos tricíclicos como inhibidores de fgfr
|
|
CA3220274A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4426286A4
(en)
*
|
2021-11-03 |
2025-12-24 |
Relay Therapeutics Inc |
Bifunctional PI3K-Alpha Inhibitors and Their Uses
|
|
WO2023098880A1
(zh)
*
|
2021-12-02 |
2023-06-08 |
上海翰森生物医药科技有限公司 |
稠环类衍生物调节剂、其制备方法和应用
|
|
KR102670554B1
(ko)
*
|
2022-01-04 |
2024-05-30 |
주식회사 이노보테라퓨틱스 |
캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물
|
|
US20250171444A1
(en)
*
|
2022-03-04 |
2025-05-29 |
Synnovation Therapeutics, Inc. |
PI3Ka INHIBITORS
|
|
EP4585596A4
(en)
*
|
2022-09-09 |
2025-12-10 |
Shanghai Yingli Pharm Co Ltd |
Nitrogen-containing heterocyclic compound, pharmaceutical composition thereof and uses thereof
|
|
WO2024153238A1
(zh)
*
|
2023-01-20 |
2024-07-25 |
南京再明医药有限公司 |
四环化合物及其应用
|
|
WO2024251212A1
(en)
*
|
2023-06-06 |
2024-12-12 |
Revir Therapeutics, Inc. |
Isoindolinone and dihydropyrrolopridinone compounds and uses thereof
|
|
WO2025179441A1
(zh)
*
|
2024-02-27 |
2025-09-04 |
上海璎黎药业有限公司 |
一种三并环结构化合物、其药物组合物及应用
|